Dr. Steven Howard has expertise in the treatment of patients with brain tumors. His research focuses on the clinical application of new radiation techniques and radiation-drug combinations to improve outcomes for brain tumor patients. Dr. Howard has received numerous awards and honors for his work in Radiation Oncology.
melanoma-sarcoma
Kristin Bradley, MD
Dr. Bradley participates in clinical research, evaluating ways to improve cancer care in patients with gynecologic, hematologic or pediatric cancers who are receiving radiation as a component of their treatment. In addition to her clinical practice, she is the Radiation Oncology Residency Program director. She is also involved with teaching medical students and undergraduates.
Michael Bassetti, MD, PhD
Dr. Bassetti is an associate professor in the Department of Human Oncology with a clinical focus on gastrointestinal cancers and research interests in MRI-guided radiation and immunotherapy. He has been developing the use of real-time MRI-guided radiation to reduce toxicity, maximize local control and improve patient outcomes. Additionally, he is involved in combining immunotherapies with anatomically targeted high-dose radiotherapy to improve the antigen specific T cell response.
Zachary Morris, MD, PhD
The Morris Lab is focused on using preclinical and translational research approaches to study the mechanisms whereby radiation may impact the anti-tumor response to immunotherapies. Their primary objective is to determine whether and how radiation may optimally be employed to simultaneously modulate the tumor immune microenvironment and to increase the susceptibility of tumor cells to immune response. They seek to test these approaches in early phase clinical studies where they may be further refined with the ultimate aim of improving survival and achieving cures in patients with metastatic cancers.
Gregory Cooley, MD
Dr. Cooley is a clinical associate professor in the Department of Human Oncology (DHO). The DHO is one of the few centers in the region offering both low-dose-rate and high-dose-rate prostate brachytherapy. Two decades ago, prostate brachytherapy showed superior PSA control rates. With further advances in dosing, fractionation and MRI-based planning, results are even better.